"From that, it will predict the likely outcomes for the patient and help the physician to determine the optimal therapy," he told Fox News Digital in an interview.The process is simple, he said. The clinician orders a test from ArteraAI’s website, then ships a biopsy sample to the company’s lab. "We are the first-ever predictive test in localized prostate cancer that can help a clinician identify the best treatment for a patient," Esteva said.
"Let's say that you’re a clinician and your patient has been diagnosed, and you’re considering whether or not you should intensify their therapy," he said. There are other tests available that take the tissue and extract some genetic material from it, but ArteraAI’s test uses a"non-destructive method," so the tissue is still intact and can be used for other things, the doctor said."One of the things we struggle with in prostate cancer, when a man is sitting in front of me, is how do I know if he's a patient that I don't even need to treat or a patient who might die of this disease?" Spratt said.
Prostate cancer is typically diagnosed via imaging scans, PSA tests and biopsies. One CEO said he does not expect the new technology to replace medical providers’ jobs."What ArteraAI does in no way affects anyone's livelihood or job," he said.